Author Archive

NPLG event on March 5, 2020

NLPG invites its members to join us for this exciting evening event focusing on opportunities and challenges related to Nordic Life Science IPOs and biotech funding. For some life sciences businesses, but surely not for all, an IPO may be the best possible scenario to secure funding, but at what cost? Is the business perhaps run even better without being listed? What are the pitfalls and what other funding opportunities may be available?

Nasdaq, Carsten Borring (Head of Listings & Capital Markets) will present their perspectives on Nordic Life Science IPOs. What key learnings has Nasdaq had for the past decades, and which trends should businesses be aware of in the years to come? Virogates, Jakob Knudsen (CEO) has kindly agreed to provide us with their experience preparing for and being a listed company. An additional pharma company is expected to provide their thoughts on Nordic IPOs.

About Nasdaq The Copenhagen Stock Exchange or CSE (Københavns Fondsbørs), since 2014 officially called Nasdaq Copenhagen, is an international marketplace for Danish securities, including shares, bonds, treasury bills and notes, and financial futures and options. Nasdaq Copenhagen is one of the Nasdaq Nordic Exchanges. Nasdaq Nordic goes back to the 2003 merger of OM AB and HEX plc to form OMX and has, since February 2008, been part of Nasdaq, Inc. (formerly known as NASDAQ OMX Group).

About Virogates ViroGates was founded in 2001, based on an invention coming from Hvidovre Hospital, Denmark. Inventor and co-founder Jesper Eugen-Olsen discovered the utility of the biomarker suPAR in HIV. More than 600 publications have followed, substantiating suPAR as one of the most promising biomarker tools for various areas of healthcare. ViroGates has developed a product line called suPARnostic® to make the suPAR test commercially available, and the ambition is to get the test implemented and used for clinical decision making.

NPLG Network Meeting November 21, 2019


We are pleased to invite you to our first post-summer seminar “Danish Innovation goes abroad” that will take place on November 21, 2019 starting at 16.30h pm (CET).


We are very pleased to have both Mads Aaboe Jensen (Roche Innovation Center Copenhagen ) and Ton Berkien (Amgen Business Development ) present to provide us with their opinions and experiences with regards to the acquisition of Santaris Pharma A/S and Nuevolution AB by Roche (2014) and Amgen (2019) respectively.



  • 16.30 – Welcome drinks
  • 17.00 – Presentations
  • 19.00 – Dinner (at your own costs, wine covered by NPLG).

Location: Comwell Holte,  Kongevejen 495A, 2840 Holte


Please inform Nicoline ( as soon as possible and latest on November 10th, 2019 whether you will be attending the meeting and dinner.

We hope to see as many of you as possible!

Upcoming NPLG events 2019/2020


Mark you calendar for the upcoming NPLG events:

  • Network meeting on November 21, 2019 from 17.00. Speaker: Ton Berkien will talk about the Amgen acquisition of Nuevolution. Location: To be announced. 
  • Network meeting on January 29, 2020 from 17.00. Speaker: To be announced. Location: To be announced. 
  • Annual assembly and network meeting on April 22, 2020Speaker: To be announced. Location: Comwell, Holte. 

We are looking forward to seeing you!

NPLG Term Sheet Workshop on 5th of March, 2019

We would like to invite you to a full day workshop for business developers and licensing professionals in life science.
The workshop will take place on 5 March, 2019 from 8.30-17 at the Maersk Tower in Copenhagen.
“What is wrong with this term sheet?” 
The workshop is interactive and will focus on term sheets for transactions closed between universities and spin-outs/pharma/life science companies. The content of a term sheet will be addressed from the perspective of all parties – inventors, universities, companies and investors.
The course content includes:
  • The term sheet – what is it used for?
  • Financial and non-financial clause important for negotiation
  • Academic term sheets versus commercial term sheets
  • Setting a call on early stage assets and IP
  • Term sheet negotiation
  • Legal aspects of drafting term sheets
Please see the invitation for more information.
We are looking forward to seeing you.

Upcoming NPLG events


We have now set the dates for the upcoming meetings and hope that you will be able to participate in the events. Please note that you must have paid your membership fee in order to participate.

  • Networking and Dinner meeting on November 21 from 17-21. Venue is Skodsborg Kurhotel. Invited speaker is Mats Blom, CFO in Zealand Pharma. Mats will present the Zealand Pharma’s recent deal with Royalty Pharma.
  • Networking and Annual General Assembly will take place on meeting on April 25, 2019. From 17-21. Speaker to be announced.
  • Workshop/full day course on Term Sheet “What is wrong with this term sheet?” will be held on March 5, 2019 from 8.30-17.00 (Program starts at 9.00). Maximum 20 attendees. Price for members EUR 950,-


NPLG Networking Dinner on May 3, 2018

Our next networking dinner meeting and general assembly will take place on Thursday, May 3, 2018. Venue is Kurhotel Skodsborg A/S, Skodsborg Strandvej 139, 2942 Skodsborg. 

The meeting will begin at 17:00 and we have the pleasure of Mathias Kroll from Bavarian Nordic coming to give a speech on the topic:

The Bavarian Nordic & Janssen Deal 2017: Combining viral vector technologies to get an edge against infectious disease”

Mathias Kroll will outline the key factors that allowed Bavarian Nordic to attract Janssen to select Bavarian Nordic’s MVA technology to combine with Janssen’s adenovector platform in order to create multiple vaccine programs against infectious disease using the adenovector/MVA in a heterologous prime/boost vaccination regimen. Moreover, high-level deal structure and financials will be outlined and implications for BN will be discussed.

 We hope to see as many of you as possible! Please confirm you attendance already now. 

NPLG Networking Dinner on January 25, 2018

Our next NPLG Networking Dinner will take place on Thursday, January 25, 2018. Venue is Kurhotel Skodsborg A/S, Skodsborg Strandvej 139, 2942 Skodsborg. 

As guest speaker, we have invited Henrik Simonsen, CFO of Nuevolution AB. The topic for the meeting will be the “Listing of life science companies on the Swedish First North – why are Danish companies turning to Sweden for IPOs?“. Ton will tell about the background for and their experiences with making an IPO on NASDAQ First North in Sweden, where the company raised SEK 250 million. Besides this main topic, the business model of Nuevolution will be discussed as well and in what way this business model facilitates long term growth in the company where biotech investors and in general capital raising initiatives go hand in hand.


17:00 Aperitif to be served outside the Meeting room

17:20 Welcome and news on NPLG and EPLG activities (Ole Wiborg)

17:30 Henrik Simonsen “Listing of life science companies on the Swedish First North – why are Danish companies turning to Sweden for IPOs?”.

18:30 Dinner served (as always paid by yourself, wine is paid by NPLG)

Please confirm your attendance soonest possible and the latest by January 19, 2018. We are looking forward to seeing you all for good discussions and a pleasant time together.

NPLG dinner and seminar “From Assumptions to Zignature” on October 26, 2017

Our next dinner and seminar will take place on the 26th of October, 2017 at Skodsborg.

We are very pleased to have both Uffe Boesen (Xplico) and Roger Lassing (LEO pharmaceuticals) present to provide us with their ins and outs on valuation “from  Assumptions to Zignature”, thereby touching upon things like valuation model building, making reasonable assumptions but also understand pitfalls wrt. misjudgements and the impact on outcomes, in addition to how to use valuation model outcomes in term sheet drafting, internal management discussion as well as in deal negotiations.

Uffe Boesen is Partner at Xplico, a Denmark based Consultancy company and a market leader in valuation support to over 75 life science companies in US and EU.

Roger Lassing is Senior Business Development Manager at LEO pharmaceuticals where is he is mainly active in working with LEO’s corporate investments and M&A.

We hope to see as many of you as possible for these exciting presentations and we expect lively discussions around these day-to-day topics for BD-ers.


15.45 – Welcome drinks

16.15 – Presentations

18.30 – Dinner (at your own costs, wine covered by NPLG).

Please confirm your attendance as soon as possible and by October 13 at the latest. We are looking forward to seeing you!

NPLG activities 2017/2018

Event agenda:

October 26, 2017: Valuation workshop and networking dinner.
Kurhotel Skodsborg A/S, Skodsborg Strandvej 139, 2942 Skodsborg
January 25, 2018: Networking dinner with Alex Haahr Gouliaev,
CEO of Nuevolution AB as speaker.
Kurhotel Skodsborg A/S, Skodsborg Strandvej 139, 2942 Skodsborg
April 19, 2018: Annual General Assembly with speaker topic
“Nordic Deal of the Year”.
Kurhotel Skodsborg A/S, Skodsborg Strandvej 139, 2942 Skodsborg
June 3, 2018: Reception at BIO 2018 (Boston,USA)
September 2018: Education seminar “Term Sheet”.

NPLG Annual General Assembly on April 27!

We are pleased to invite you to our Annual General Assembly that will take place on April 27, 2017 starting at 5 pm.

The meeting will take place at:

Skodsborg Kurhotel, Skodsborg Strandvej 139, 2942 Skodsborg

We have been so fortunate to get Jette Asboe Lassen from Symphogen to give a presentation on their deal with Baxalta (now Shire) concerning 6 checkpoint cancer therapy targets and what it has meant to Symphogen. This was one of the most significant biotech deals in 2016 with a deal value of $ 1.6 billion including an upfront payment of $ 175 million. We hope to see as many of you as possible for this exciting presentation.


17.00 – Welcome drinks

17.30 – General Assembly

  1. Review of 2016 activities (O.Wiborg) 
  2. Presentation of Annual NPLG accounts (J.Aakersø) 
  3. Election of the NPLG Board. Early 2016 we lost Morten Fäster from the Board as he got a new position in Germany. The current Board members (Jens Aakersøe, Jan Bjerrum Bach, Ole Wiborg and Jürgen Langharig) are all willing to continue but we strongly hope that there are one or two candidates willing to join the Board.
  4. Activities 2017/2018

17.50 – Presentation – Jette Asboe Lassen, Director of Business Development, Symphogen: “The Symphogen-Baxalta deal”

18.30 – Dinner (at your own costs, wine covered by NPLG).

We are looking forward to seeing you!